ArticleTranslational vision science & technology2025
Three-Dimensional Choroidal Vessels Assessment in Fellow Eyes of Patients With Central Serous Chorioretinopathy.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Radiomics-based fundus autofluorescence analysis in central serous chorioretinopathy-MICRoN report number twelve.Scientific reports · 2026Article
- Quantitative evaluation of the topographical maps of three-dimensional choroidal vascularity index in gestational diabetes mellitus: a cross-sectional observational study.BMC pregnancy and childbirth · 2026Observational
- Retinal and choroidal vascular density alterations in patients with schizophrenia: assessment via optical coherence tomography angiography.BMC psychiatry · 2026Article
- Structural and microvascular alterations in clinically unaffected fellow eyes of patients with acute central serous chorioretinopathy: An OCT and OCTA study.Northern clinics of Istanbul · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Purpose: To evaluate choroidal vasculature using a novel three-dimensional algorithm in fellow eyes of patients with unilateral chronic central serous chorioretinopathy (cCSC). Methods: Patients with unilateral cCSC were retrospectively included. Automated choroidal segmentation was conducted using a deep-learning ResUNet model. Phansalkar thresholding was applied to binarize choroidal vasculature, and three-dimensional maps were created. Mean choroidal vessel diameter, intervessel distance, choroidal thickness, and choroidal vascularity index (CVI) were measured. Linear mixed models were used for statistical analysis. Results: Thirty unilateral cCSC eyes, 22 fellow, and 26 controls were included. Both cCSC and fellow eyes exhibited significant higher mean choroidal vessel diameter compared with controls (362.50 ± 83.23 µm, 276.84 ± 26.89 µm, and 233.28 ± 28.18 µm, respectively; P < 0.001), and in choroidal thickness (288.90 ± 64.77 µm, 269.76 ± 71.17 µm, and 223.97 ± 43.40 µm, respectively; P = 0.001). The intervessel distance was reduced in cCSC and fellow eyes compared with controls (196.53 ± 23.58 µm, 225.05 ± 33.72 µm, and 264.13 ± 46.06 µm, respectively; P < 0.001). Although lower, the CVI was not significantly different in cCSC and fellow eyes compared with controls (38.14 ± 5.55%, 37.23 ± 6.41%, and 40.65 ± 3.53%, respectively; P = 0.066), indicating a possible trend toward a lower CVI. Conclusions: Three-dimensional representation of choroidal vasculature revealed significant changes in both cCSC and fellow eyes, including a larger diameter and reduced spacing compared with healthy controls. Translational Relevance: Using a validated deep learning-based three-dimensional method, we observed changes in the choroidal vasculature in both CSC and fellow eyes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.